IGC Pharma's Alzheimer's Agitation Drug Candidate Now Patented in the U.S., Canada, and Mexico as Phase 2 Readout Nears

Patent coverage now spans all three North American markets, while Phase 2 topline results await database lock and unblinding.

Rhea-AI Summary

IGC Pharma (NYSE American: IGC) received a Canadian patent covering the composition of IGC-AD1, its investigational oral therapy for Alzheimer's agitation. Canadian Patent No. 3,095,729, titled “Method and Composition for Treating CNS Disorders,” extends issued protection from the same patent family across the United States, Canada and Mexico. IGC-AD1 has 5 granted patents in total, with 10 more applications pending worldwide.

IGC-AD1 is being evaluated in CALMA, a randomized, double-blind, placebo-controlled Phase 2 trial for agitation in Alzheimer's dementia. Enrollment was completed in September 2026, and the trial is in its final dosing period. Topline results will follow database lock and unblinding. The company aims to combine clinical evidence and patent protection to attract pharmaceutical partners for further development.

Positive

• Minor pointCanadian composition patent granted, extending same-family issued protection across the United States, Canada and Mexico.
• Minor pointIGC-AD1's portfolio totals 5 granted patents.
• Minor pointCALMA completed enrollment in September 2026 and is in its final dosing period.
• Minor point. Forward-looking: it has not happened yet and may not happen.IGC Pharma aims to attract pharmaceutical partners to advance IGC-AD1 development.

Negative

• Minor point10 additional patent applications remain pending worldwide.
• Minor point. Forward-looking: it has not happened yet and may not happen.CALMA topline results await database lock and unblinding.

Argus 15 min delay 4 alerts

-3.13% vs previous close $0.1889 last price 2.2x rel. volume Open Argus

Details

Market Reaction – IGC

$0.19 – $0.21 Day Range

$19.53M Mkt Cap at Last Price

On Nov 5, the day this news came out, the latest delayed price for IGC is 3.13% below the previous close. Our momentum scanner has recorded 4 alerts for this stock so far that day. The latest delayed price is $0.19. Relative volume is elevated at 2.2x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Granted patents: 5 granted patents Pending applications: 10 applications Patent coverage: 3 North American markets +1 more

Granted patents

5 granted patents

IGC-AD1 worldwide

Pending applications

10 applications

Worldwide, for IGC-AD1

Patent coverage

3 North American markets

United States, Canada, and Mexico

Trial phase

Phase 2

CALMA trial for agitation in Alzheimer's dementia

Previous Clinical trial Reports

1 past event · Latest: Sep 28

Same Type 1 event

1. Sep 28

   Trial enrollment

   24h Move

   -3.0%

   Completed CALMA enrollment of 168 participants; topline results were expected in Q4 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

cb1 receptor, neuroinflammation, double-blind, placebo-controlled, +1 more

5 terms

cb1 receptor medical

"including neuroinflammation, CB1 receptor signaling, and neurotransmitter regulation"

A CB1 receptor is a protein found mainly on nerve and brain cells that acts like a lock for specific chemical 'keys' called cannabinoids, including natural molecules the body makes and compounds like THC. It helps control appetite, pain, mood, memory and movement, so drugs that activate or block CB1 can change these functions. Investors watch CB1 because it is a common drug target and can drive therapeutic value, safety profiles, regulatory review, and market potential for treatments.

neuroinflammation medical

"including neuroinflammation, CB1 receptor signaling, and neurotransmitter regulation"

Neuroinflammation is the brain or spinal cord’s immune reaction to injury, infection, or abnormalities, where cells and molecules become active to protect or repair nervous tissue. It matters to investors because it underlies many neurological diseases and is a common target for drugs and diagnostic tools; positive or negative trial results, safety signals, or new therapies can change a company’s value much like a major repair plan or recall would affect a carmaker’s prospects.

double-blind medical

"a randomized, double-blind, placebo-controlled Phase 2 trial"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"a randomized, double-blind, placebo-controlled Phase 2 trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

database lock technical

"Topline results will follow database lock and unblinding."

A database lock is the point in a clinical trial when the collected study data are finalized and no further changes or corrections are allowed, so analysts can run the official statistical tests. For investors this matters because it usually precedes public results or regulatory filings—think of it like sealing and signing off an exam before grading: once locked, the timing and content of the readout become clearer and uncertainty about last-minute data edits is reduced.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

POTOMAC, MD / ACCESS Newswire / November 5, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI) enabled healthcare technologies, today announced that the Canadian Intellectual Property Office granted Canadian Patent No. 3,095,729, "Method and Composition for Treating CNS Disorders".

The patent covers the composition of IGC-AD1, an investigational oral therapy for agitation in Alzheimer's.

With this grant, IGC-AD1 is protected by issued patents from the same patent family in all three North American markets: the United States (U.S. Patent No. 12,465,589), Canada, and Mexico (Mexican Patent No. 409,414). In total, IGC-AD1 is protected by 5 granted patents, with 10 more applications pending worldwide.

"Strong patent protection is central to our strategy for IGC-AD1," said Ram Mukunda, CEO of IGC Pharma. "These patents strengthen our intellectual property portfolio. Our vision is to combine compelling clinical evidence with patent protection that supports long-term commercial value and helps attract major pharmaceutical partners to advance development and, if approved, expand patient access."

IGC-AD1 is being evaluated in CALMA, a randomized, double-blind, placebo-controlled Phase 2 trial for agitation in Alzheimer's dementia. CALMA completed enrollment in September 2026 and is in its final dosing period. Topline results will follow database lock and unblinding.

Agitation affects a large share of people living with Alzheimer's disease and is one of the hardest parts of the disease for families and caregivers to manage. IGC-AD1 is an investigational oral liquid designed to address multiple biological mechanisms implicated in agitation, including neuroinflammation, CB1 receptor signaling, and neurotransmitter regulation.

About IGC Pharma, Inc.

IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. Supported by its patent portfolio and commitment to innovation, IGC Pharma is advancing breakthrough therapies.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding completion of dosing and patient follow-up in the Phase 2 CALMA trial evaluating IGC-AD1 for agitation in Alzheimer's dementia; the timing of database lock, unblinding, topline analysis, and reporting of results; potential further clinical development and regulatory submissions; and the Company's patent protection and partnering plans. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially, including delays in trial completion, data collection, verification, and analysis; uncertainties regarding the safety and efficacy of IGC-AD1 and whether CALMA will meet its endpoints; the need for additional clinical trials and regulatory review; financing needs; risks that issued patents may be challenged, narrowed, or circumvented; and other factors discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-KT and Quarterly Reports on Form 10-Q. There can be no assurance regarding the timing or outcome of the CALMA trial, regulatory approval, commercialization, or any pharmaceutical partnership. IGC-AD1 is investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. The Company undertakes no obligation to update forward-looking statements except as required by law.

Investor Relations Contact

Andres Sanchez / Investor Relations
+1 301-983-0998 / +1 (202) 569-2566
info@igcpharma.com

Media: Kiran Mukunda, kmukunda@igcpharma.com

SOURCE: IGC Pharma, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does IGC Pharma's new Canadian IGC-AD1 patent cover?

Canadian Patent No. 3,095,729, titled “Method and Composition for Treating CNS Disorders,” covers the composition of IGC-AD1. Issued patents from the same family now protect the investigational therapy in the United States, Canada and Mexico.

When will IGC Pharma report CALMA Phase 2 results?

CALMA topline results will follow database lock and unblinding. The Phase 2 trial completed enrollment in September 2026 and is in its final dosing period.